Spots Global Cancer Trial Database for idelalisib
Every month we try and update this database with for idelalisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | NCT02258529 | Follicular Lymp... Small Lymphocyt... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | NCT01539512 | Chronic Lymphoc... | Idelalisib Rituximab Placebo to matc... | 18 Years - | Gilead Sciences | |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | NCT03151057 | B Cells-Tumors B Cell Chronic ... Follicular Lymp... Mantle Cell Lym... Large B-Cell Di... | Idelalisib 100 ... Placebo Oral Ta... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pembrolizumab + Idelalisib for Lung Cancer Study | NCT03257722 | Non Small Cell ... Metastasis Recurrence | Pembrolizumab Idelalisib | 18 Years - | Augusta University | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | NCT03742323 | Acute Lymphobla... | Idelalisib | 18 Years - | PETHEMA Foundation | |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | NCT01393106 | Hodgkin Lymphom... | Idelalisib | 12 Years - | Gilead Sciences | |
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | NCT02662296 | Prolymphocytic ... Recurrent Chron... Recurrent Non-H... Recurrent Small... | Ibrutinib Idelalisib | 18 Years - | Fred Hutchinson Cancer Center | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | NCT02044822 | B-cell Chronic ... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | NCT03349346 | Diffuse Large B... Mediastinal B-c... | Idelalisib Rituximab Ifosfamide Carboplatin Etoposide | 1 Year - 18 Years | Gilead Sciences | |
| Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma | NCT03576443 | Diffuse Large B... | Idelalisib | 19 Years - | Nordic Lymphoma Group | |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | NCT03349346 | Diffuse Large B... Mediastinal B-c... | Idelalisib Rituximab Ifosfamide Carboplatin Etoposide | 1 Year - 18 Years | Gilead Sciences | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | NCT02457598 | B-cell Malignan... | Tirabrutinib Idelalisib Entospletinib Obinutuzumab | 18 Years - | Gilead Sciences | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma | NCT03568929 | Follicular Non-... | Idelalisib | 18 Years - | Gilead Sciences | |
| Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma | NCT03576443 | Diffuse Large B... | Idelalisib | 19 Years - | Nordic Lymphoma Group | |
| REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | NCT03742323 | Acute Lymphobla... | Idelalisib | 18 Years - | PETHEMA Foundation | |
| Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma | NCT03568929 | Follicular Non-... | Idelalisib | 18 Years - | Gilead Sciences | |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | NCT03151057 | B Cells-Tumors B Cell Chronic ... Follicular Lymp... Mantle Cell Lym... Large B-Cell Di... | Idelalisib 100 ... Placebo Oral Ta... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas | NCT02332980 | Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac... | Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic | |
| Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | NCT01980888 | Chronic Lymphoc... | Idelalisib Bendamustine Rituximab Placebo | 18 Years - | Gilead Sciences | |
| Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | NCT03582098 | Chronic Lymphoc... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | NCT02787369 | Recurrent Chron... | ACY-1215 Ibrutinib Idelalisib | 18 Years - | Dana-Farber Cancer Institute | |
| Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma | NCT01644799 | Recurrent Folli... | idelalisib lenalidomide | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | NCT02779283 | Acute Lymphobla... Acute Myeloid L... | Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Idarubicin Idelalisib In Vitro Kinase... Leucovorin Calc... Methotrexate Methylprednisol... Ponatinib Hydro... Rituximab Ruxolitinib Pho... Sorafenib Tosyl... Sunitinib Malat... Vincristine Sul... | 18 Years - 64 Years | OHSU Knight Cancer Institute | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | NCT05725200 | Metastatic Colo... | Alectinib Cetuximab Crizotinib Dasatinib Everolimus Encorafenib Gemcitabine Idelalisib Larotrectinib Methotrexate Palbociclib Panobinostat Pembrolizumab Petrozumab Trastuzumab Talazoparib Venetoclax | 18 Years - | Oslo University Hospital | |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | NCT01393106 | Hodgkin Lymphom... | Idelalisib | 12 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | NCT02044822 | B-cell Chronic ... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | NCT06205290 | Leukemia, Lymph... | Liso-cel Idelalisib Rituximab Bendamustine Fludarabine Cyclophosphamid... | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | NCT03349346 | Diffuse Large B... Mediastinal B-c... | Idelalisib Rituximab Ifosfamide Carboplatin Etoposide | 1 Year - 18 Years | Gilead Sciences | |
| Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT01088048 | Indolent Non-Ho... Chronic Lymphoc... Mantle Cell Lym... | Idelalisib Rituximab Bendamustine Ofatumumab Fludarabine Everolimus Bortezomib Chlorambucil Lenalidomide | 18 Years - | Gilead Sciences | |
| Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | NCT02136511 | Chronic Lymphoc... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Pembrolizumab + Idelalisib for Lung Cancer Study | NCT03257722 | Non Small Cell ... Metastasis Recurrence | Pembrolizumab Idelalisib | 18 Years - | Augusta University | |
| Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib | NCT02824159 | Hematological M... | Blood samples f... Imagery Quality of life... Detection of ad... Saliva samples Blood sample Biological stat... Clinical examin... | 18 Years - | University Hospital, Toulouse | |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | NCT02787369 | Recurrent Chron... | ACY-1215 Ibrutinib Idelalisib | 18 Years - | Dana-Farber Cancer Institute | |
| Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT02968563 | Chronic Lymphoc... | Tirabrutinib Idelalisib Obinutuzumab | 18 Years - | Gilead Sciences | |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma | NCT04699461 | Relapsed Follic... Refractory Foll... | Loncastuximab T... Idelalisib | 18 Years - | ADC Therapeutics S.A. | |
| Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | NCT01980875 | Chronic Lymphoc... | Idelalisib Chlorambucil Obinutuzumab | 18 Years - | Gilead Sciences | |
| Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 | NCT02739360 | Lymphoid Malign... | Idelalisib | 18 Years - | Gilead Sciences | |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | NCT02787369 | Recurrent Chron... | ACY-1215 Ibrutinib Idelalisib | 18 Years - | Dana-Farber Cancer Institute | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | NCT06205290 | Leukemia, Lymph... | Liso-cel Idelalisib Rituximab Bendamustine Fludarabine Cyclophosphamid... | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | NCT02603445 | Follicular Lymp... | BCL201 Idelalisib | 18 Years - | Novartis | |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma | NCT04699461 | Relapsed Follic... Refractory Foll... | Loncastuximab T... Idelalisib | 18 Years - | ADC Therapeutics S.A. | |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas | NCT02332980 | Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac... | Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic | |
| A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | NCT01203930 | Chronic Lymphoc... Small Lymphocyt... | Idelalisib Rituximab | 65 Years - | Gilead Sciences | |
| Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia | NCT02962401 | Waldenstrom Mac... | Obinutuzumab Idelalisib | 18 Years - | French Innovative Leukemia Organisation | |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) | NCT02242045 | Chronic Lymphoc... Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 20 Years - | Gilead Sciences | |
| Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia | NCT02962401 | Waldenstrom Mac... | Obinutuzumab Idelalisib | 18 Years - | French Innovative Leukemia Organisation | |
| Dose Optimization Study of Idelalisib in Follicular Lymphoma | NCT02536300 | Follicular Lymp... | Idelalisib | 18 Years - | Gilead Sciences | |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | NCT02258529 | Follicular Lymp... Small Lymphocyt... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | NCT02457598 | B-cell Malignan... | Tirabrutinib Idelalisib Entospletinib Obinutuzumab | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | NCT02044822 | B-cell Chronic ... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia | NCT02962401 | Waldenstrom Mac... | Obinutuzumab Idelalisib | 18 Years - | French Innovative Leukemia Organisation | |
| Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma | NCT03568929 | Follicular Non-... | Idelalisib | 18 Years - | Gilead Sciences | |
| Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | NCT03582098 | Chronic Lymphoc... | Idelalisib Rituximab | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
